Skip Nav Destination
Issues
1 July 2017
-
Cover Image
Cover Image
ABOUT THE COVER
Carcinomas develop in a complex tumor microenvironment (TME) that includes a diverse spectrum of cell types that influence tumor cell behavior. Notably, in response to genotoxic cancer-directed therapeutics, proliferating tumor cells undergo a complex but coordinated response leading to repair, senescence, or apoptosis. In contrast to tumor cells, the vast majority of benign cells in the TME, including fibroblasts and vascular endothelium, are quiescent, and initiate a damage response program that includes the secretion of cytokines and growth factors capable of promoting the resistance of surviving tumor cells to further cycles of treatment. The cover image shows the expression of genes involved in cell cycle progression (CCP) in microdissected cell populations from prostate cancers that comprise benign prostate epithelial cells, cancer adjacent stroma, and carcinoma. In comparison to prostate cancer, benign epithelium and cells in the prostate stroma exhibit very low CCP activity, indicating they are in a Go, quiescent, terminally differentiated state. Please see the article by Gomez-Sarosi and colleagues (beginning on page 842) for more information. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1541-7786
EISSN 1557-3125
Molecular Cancer Research
Table of Contents
Highlights
Cell Cycle and Senescence
Chromatin, Epigenetics, and RNA Regulation
DNA Damage and Repair
Genomics
Metabolism
Oncogenes and Tumor Suppressors
Author Choice
Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal Carcinoma
Yozo Mitsui; Hiroaki Shiina; Taku Kato; Shigekatsu Maekawa; Yutaka Hashimoto; Marisa Shiina; Mitsuho Imai-Sumida; Priyanka Kulkarni; Pritha Dasgupta; Ryan Kenji Wong; Miho Hiraki; Naoko Arichi; Shinichiro Fukuhara; Soichiro Yamamura; Shahana Majid; Sharanjot Saini; Guoren Deng; Rajvir Dahiya; Koichi Nakajima; Yuichiro Tanaka
Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer
Lisa Maria Mustachio; Yun Lu; Laura J. Tafe; Vincent Memoli; Jaime Rodriguez-Canales; Barbara Mino; Pamela Andrea Villalobos; Ignacio Wistuba; Hiroyuki Katayama; Samir M. Hanash; Jason Roszik; Masanori Kawakami; Kwang-jin Cho; John F. Hancock; Fadzai Chinyengetere; Shanhu Hu; Xi Liu; Sarah J. Freemantle; Ethan Dmitrovsky
Signal Transduction
Journal Archive
Molecular Cancer Research
(2002-Present; volumes 1-current)Published monthly since November, 2002.
(ISSN 0008-5472)
Cell Growth & Differentiation
(1990-2002; volumes 1-13)Published monthly 1990- September, 2002.
(ISSN 1044-9523)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.